Persistent symptoms up to four months after community and hospital-managed SARS-CoV-2 infection
Publication Details
Darley, D. R.,
Dore, G. J.,
Cysique, L. A.,
Wilhelm, K.,
Andresen, D.,
Tonga, K.,
Stone, E.,
Byrne, A.,
&
Matthews, G.
(2021).
Persistent symptoms up to four months after community and hospital-managed SARS-CoV-2 infection.
Medical Journal of Australia, 214 (6), 279-280.
Abstract
The spectrum of recovery for people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains uncertain.1-4 The ADAPT study is a prospective cohort study that follows up all adults diagnosed with coronavirus disease 2019 (COVID-19) at St Vincent’s Hospital, Sydney. Our goal is to characterise the effects of infection during the 12 months after diagnosis, by initial severity of COVID-19. Our specific aims were to determine the prevalence and nature of persistent symptoms; to evaluate lung function, health-related quality of life, neurocognitive and olfactory abnormalities during the recovery period; and to characterise the longitudinal immune response to infection.
In this article, we report the results of assessments performed up to four months after diagnosis. All adults with SARS-CoV-2 infections confirmed by polymerase chain reaction (PCR) at St Vincent’s Hospital testing clinics and who could be contacted were invited to participate. Participants were prospectively assessed according to a pre-defined schedule. The study was approved by the St Vincent’s Hospital Human Research Ethics Committee (reference, 2020/ETH00964); baseline visits commenced as soon as this approval was obtained.
Keywords
SARS-CoV-2, Covid-19, Signs and symptoms, Neurocognitive disorders, Lung disease, Virology
Link to Publisher Version (URL)
